Pregnancy Risk Category C
How supplied
Tablets: 75 mg
Capsules: 150 mg, 300 mg
Action
Competitively inhibits action of H2 at receptor sites of the parietal cells, decreasing gastric acid secretion.
Indications & dosage
Active duodenal ulcer--
Adults: 300 mg P.O. daily h.s. Or, 150 mg P.O. b.i.d.
Maintenance therapy for duodenal
ulcer--
Adults: 150 mg P.O. daily h.s.
Benign gastric ulcer--
Adults: 150 mg P.O. b.i.d. or 300 mg h.s. for 8 weeks.
Gastroesophageal reflux disease (GERD)--
Adults: 150 mg P.O. b.i.d. for up to 12 weeks.
Adjust-a-dose: For renally impaired patients with creatinine clearance of 20 to 50 ml/minute, 150 mg P.O. daily for treatment of active duodenal ulcer, benign gastric ulcer, or GERD; or 150 mg every other day for maintenance therapy. If creatinine clearance is below 20 ml/minute, 150 mg P.O. every other day for treatment, or 150 mg every third day for maintenance.
Adverse reactions
CNS: somnolence.
CV: arrhythmias.
Hematologic: eosinophilia.
Hepatic: elevated liver function tests results, hepatocellular injury.
Metabolic: hyperuricemia.
Skin: diaphoresis, rash, urticaria.
Other: fever.
Interactions
Drug-drug. Aspirin: possibly elevated serum salicylate levels (with high doses). Monitor closely.
Drug-food. Tomato-based vegetable juices: may decrease potency of drug when used concomitantly. Don't use together.
Effects on diagnostic tests
False-positive test results for urobilinogen may occur during drug therapy.
Contraindications
Contraindicated in patients with hypersensitivity to H2-receptor antagonists.
Nursing considerations
Patient teaching
*Liquid contains alcohol. **May contain tartrazine. †Canada ‡Australia §U.K. OTCOver the counter
Reactions may be common, uncommon, life-threatening, or COMMON AND LIFE-THREATENING